260 related articles for article (PubMed ID: 29077926)
1. No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.
Perrier M; Visseaux B; Landman R; Joly V; Todesco E; Yazdanpanah Y; Calvez V; Marcelin AG; Descamps D; Charpentier C
J Antimicrob Chemother; 2018 Jan; 73(1):173-176. PubMed ID: 29077926
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 protease, Gag and gp41 baseline substitutions associated with virological response to a PI-based regimen.
Perrier M; Castain L; Regad L; Todesco E; Landman R; Visseaux B; Yazdanpanah Y; Rodriguez C; Joly V; Calvez V; Marcelin AG; Descamps D; Charpentier C
J Antimicrob Chemother; 2019 Jun; 74(6):1679-1692. PubMed ID: 30768160
[TBL] [Abstract][Full Text] [Related]
3. Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.
Lataillade M; Chiarella J; Yang R; DeGrosky M; Uy J; Seekins D; Simen B; St John E; Moreno E; Kozal M
PLoS One; 2012; 7(2):e30118. PubMed ID: 22355307
[TBL] [Abstract][Full Text] [Related]
4. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.
Descamps D; Lambert-Niclot S; Marcelin AG; Peytavin G; Roquebert B; Katlama C; Yeni P; Felices M; Calvez V; Brun-Vézinet F
J Antimicrob Chemother; 2009 Mar; 63(3):585-92. PubMed ID: 19147519
[TBL] [Abstract][Full Text] [Related]
5. New mechanisms of resistance in virological failure to protease inhibitors: selection of non-described protease, Gag and Gp41 mutations.
Castain L; Perrier M; Charpentier C; Palich R; Desire N; Wirden M; Descamps D; Sayon S; Landman R; Valantin MA; Joly V; Peytavin G; Yazdanpanah Y; Katlama C; Calvez V; Marcelin AG; Todesco E
J Antimicrob Chemother; 2019 Jul; 74(7):2019-2023. PubMed ID: 31050739
[TBL] [Abstract][Full Text] [Related]
6. From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.
Namakoola I; Kasamba I; Mayanja BN; Kazooba P; Lutaakome J; Lyagoba F; Kapaata AA; Kaleebu P; Munderi P;
BMC Res Notes; 2016 Dec; 9(1):515. PubMed ID: 28010730
[TBL] [Abstract][Full Text] [Related]
7. Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).
Lambert-Niclot S; Grude M; Chaix ML; Charpentier C; Reigadas S; Le Guillou-Guillemette H; Rodallec A; Amiel C; Maillard A; Dufayard J; Mourez T; Mirand A; Guinard J; Montes B; Vallet S; Marcelin AG; Descamps D; Flandre P; Delaugerre C; Morand-Joubert L;
J Antimicrob Chemother; 2018 Aug; 73(8):2147-2151. PubMed ID: 29718247
[TBL] [Abstract][Full Text] [Related]
8. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
Jao J; Yu W; Patel K; Miller TL; Karalius B; Geffner ME; DiMeglio LA; Mirza A; Chen JS; Silio M; McFarland EJ; Van Dyke RB; Jacobson D;
HIV Med; 2018 Mar; 19(3):175-183. PubMed ID: 29159965
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Borghetti A; Lombardi F; Gagliardini R; Baldin G; Ciccullo A; Moschese D; Emiliozzi A; Belmonti S; Lamonica S; Montagnani F; Visconti E; De Luca A; Di Giambenedetto S
BMC Infect Dis; 2019 Jan; 19(1):59. PubMed ID: 30654739
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
[TBL] [Abstract][Full Text] [Related]
11. Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K; Perry CM; Keam SJ
Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.
Ryom L; Lundgren JD; El-Sadr W; Reiss P; Kirk O; Law M; Phillips A; Weber R; Fontas E; d' Arminio Monforte A; De Wit S; Dabis F; Hatleberg CI; Sabin C; Mocroft A;
Lancet HIV; 2018 Jun; 5(6):e291-e300. PubMed ID: 29731407
[TBL] [Abstract][Full Text] [Related]
13. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
[TBL] [Abstract][Full Text] [Related]
15. Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients.
Antoniou T; Szadkowski L; Walmsley S; Cooper C; Burchell AN; Bayoumi AM; Montaner JS; Loutfy M; Klein MB; Machouf N; Tsoukas C; Wong A; Hogg RS; Raboud J;
BMC Infect Dis; 2017 Apr; 17(1):266. PubMed ID: 28399819
[TBL] [Abstract][Full Text] [Related]
16. Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.
Pozniak A; Opravil M; Beatty G; Hill A; de Béthune MP; Lefebvre E
AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1275-80. PubMed ID: 18844462
[TBL] [Abstract][Full Text] [Related]
17. Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study.
Dolling DI; Dunn DT; Sutherland KA; Pillay D; Mbisa JL; Parry CM; Post FA; Sabin CA; Cane PA; ;
J Antimicrob Chemother; 2013 Oct; 68(10):2339-43. PubMed ID: 23711895
[TBL] [Abstract][Full Text] [Related]
18. An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir.
Laker EAO; Nabaggala MS; Kaimal A; Nalwanga D; Castelnuovo B; Musubire A; Kiragga A; Lamorde M; Ratanshi RP
BMC Infect Dis; 2019 Mar; 19(1):280. PubMed ID: 30909871
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
[TBL] [Abstract][Full Text] [Related]
20. Major drug resistance mutations to HIV-1 protease inhibitors (PI) among patients exposed to PI class failing antiretroviral therapy in São Paulo State, Brazil.
Soldi GFR; Ribeiro IC; Ahagon CM; Coelho LPO; Cabral GB; Lopes GISL; Ferreira JLP; Brígido LFM;
PLoS One; 2019; 14(10):e0223210. PubMed ID: 31574109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
